Mounjaro stomach paralysis symptoms: what you should know

Does Mounjaro actually slow the stomach down, and is that the same as gastroparesis?

Tirzepatide, sold in the UK as Mounjaro, acts on two gut-hormone receptors (GIP and GLP-1) and one of the things both pathways do is reduce how quickly the stomach pushes food into the small intestine. That slower transit helps you feel full sooner and for longer. It is intentional, and for most people it simply means meals feel more satisfying at smaller portions.

Gastroparesis is something different. It refers to a condition in which the stomach's muscular activity is impaired enough that food sits there abnormally long — not just delayed, but genuinely stalled. That can cause a recognisable cluster of symptoms: nausea that does not resolve after eating, vomiting of partially digested or undigested food hours after a meal, a sensation of fullness that arrives with only a few bites, abdominal bloating, and sometimes upper stomach pain or discomfort. Weight loss that is faster or more drastic than expected can occasionally be a signal, too.

The honest picture is that tirzepatide does not cause gastroparesis in the way a nerve injury might. What it does is slow gastric emptying, and in a small number of people that slowing is pronounced enough to produce symptoms that overlap with gastroparesis. The NHS tirzepatide medicine page lists nausea, vomiting, and stomach discomfort among the known side effects, and notes these are most likely at the start of treatment or after a dose increase. For most people they are temporary. For a smaller group, they can be more persistent.

How do you tell normal side effects from something that needs attention?

This is the question that genuinely matters, and it is reasonable to feel uncertain. Nausea in the first week or two after starting treatment, or after moving up a dose, is very common and typically settles. Feeling full after a modest portion is expected. These are the gastric-slowing effects working as described. They are uncomfortable but not dangerous for most people.

The pattern that warrants a call to your prescriber or GP is different. It includes: vomiting that happens repeatedly, particularly if you are bringing up food eaten many hours earlier; nausea that does not ease between meals or persists beyond two to three weeks at a stable dose; an inability to tolerate solid food or even fluids without vomiting; signs of dehydration such as dark urine, dizziness, or a dry mouth that does not improve. Significant abdominal pain (particularly severe pain that radiates through to the back) needs same-day medical assessment. The MHRA issued specific guidance in January 2026 highlighting acute pancreatitis as a serious but infrequent risk with GLP-1 medicines: the symptom to watch for is severe, persistent stomach pain that may spread to the back, with or without vomiting. That presentation needs urgent care, not watchful waiting.

You can find a broader overview of symptoms to watch for on Mounjaro on a dedicated page if you want the wider picture, and if you have noticed urinary symptoms alongside digestive ones, our page on Mounjaro and UTI symptoms explains what the research currently says about that connection.

What happens if gastroparesis-type symptoms persist?

A prescriber has several options. The most common is pausing the dose escalation and staying at the current or a lower dose until symptoms settle. In some cases that means staying at a lower dose for longer before attempting to move up again; in others it means stepping back to a previous dose. Dietary adjustments are usually recommended alongside any clinical change: smaller, more frequent meals; softer, lower-fat foods that empty more easily; keeping well hydrated between meals rather than drinking large amounts with food. These are not substitutes for clinical advice, they are the kinds of adjustments a prescriber or dietitian would typically guide you through.

There is a separate, more detailed look at how gastroparesis and Mounjaro relate clinically if you want to go deeper on the evidence. The question of what happens when you stop tirzepatide (including whether gastric emptying returns to its previous rate) is addressed on our page covering coming off Mounjaro symptoms. Gastric function generally normalises after stopping, though the timeline varies by individual.

Understanding the cost context of staying on treatment long enough for it to work is also practical, you can read an honest breakdown on our Mounjaro cost page, which covers what is typically included in a legitimate private prescription service.

Suspected side effects, including any pattern of symptoms you find concerning, can be reported directly to the MHRA via the Yellow Card scheme. That reporting matters, it shapes how regulators understand the real-world profile of newer medicines.

Should you stop Mounjaro if you think these symptoms are happening to you?

Not without speaking to a prescriber first. Stopping abruptly is rarely necessary and, in most cases, the right step is to contact whoever manages your prescription and describe exactly what you are experiencing, including when it started, how often it happens, and what makes it better or worse. If symptoms are severe enough that you cannot keep fluids down, you are in pain, or you feel unwell in a way that goes beyond digestive discomfort, the right call is a GP or NHS 111 rather than waiting for a scheduled review.

The tirzepatide medicines used for weight management are prescribed and monitored precisely because this kind of clinical judgement matters. A prescriber does not just approve a starting dose and step back, they need to hear about changes like these. At nume, our clinical team reviews every repeat order individually, and any concern raised through aftercare reaches a real prescriber. If you have questions about how that works or want to speak to someone before starting, our page on weight loss treatments explains the consultation process in full.